Eklund, Mikael http://orcid.org/0000-0002-1947-712X
Nuuttila, Simo
Joutsa, Juho
Jaakkola, Elina
Mäkinen, Elina
Honkanen, Emma A.
Lindholm, Kari
Vahlberg, Tero
Noponen, Tommi
Ihalainen, Toni
Murtomäki, Kirsi
Nojonen, Tanja
Levo, Reeta
Mertsalmi, Tuomas
Scheperjans, Filip
Kaasinen, Valtteri
Clinical trials referenced in this document:
Documents that mention this clinical trial
Diagnostic value of micrographia in Parkinson’s disease: a study with [123I]FP-CIT SPECT
https://doi.org/10.1007/s00702-022-02517-1
Diagnostic accuracy of glabellar tap sign for Parkinson’s disease
https://doi.org/10.1007/s00702-021-02391-3
Funding for this research was provided by:
Turun Yliopistollinen Keskussairaala
Päivikki ja Sakari Sohlbergin Säätiö
The Finnish Alcohol Research Foundation
The Finnish Parkinson Foundation
The Turku University Foundation
University of Turku (UTU) including Turku University Central Hospital
Article History
Received: 23 February 2022
Accepted: 11 May 2022
First Online: 27 May 2022
Declarations
:
: The authors report no competing interests. Mikael Eklund reports grants from the Finnish Parkinson Foundation (FPF), Turku University Hospital (TUH) and Finnish Medical Foundation (FMF) and pending grant applications from Funding: Maire Taponen Foundation and Finnish Brain Foundation related to submitted work. Simo Nuuttila reports grants from FPF, TUH, The Päivikki and Sakari Sohlberg Foundation (PSSF) and Finnish Alcohol Research Foundation (FARF), payment for manuscript writing from Turunmaan Duodecim association, support for attending a meeting from Turku University Foundation (TUF) Kosti Hämmärö fund, outside of submitted work. Elina Jaakkola reports grants from FPF outside of submitted work. Elina Mäkinen reports grants from FPF, TUF and Finnish Cultural Foundation (FCF) outside of submitted work. Emma Honkanen reports grants from TUF, TUH, FPF and FMF outside submitted work. Kirsi Murtomäki reports grants from FPF and The Hopital District of Helsinki and Uusimaa (HUS). Tuomas Mertsalmi reports grants from FPF, Finnish Norwegian Medical Foundation (FNMF) and Elias Aaltonen Foundation (EAF). Valtteri Kaasinen reports grants from FCF, PSSF, TUH related to submitted work and FARF outside of submitted work, consulting fees from Nordic Infucare Ab, Abbvie, Adamant Health and Orion Pharma, payments from Nordic Infucare, Abbvie and GE Healthcare, payment for expert testimony and support for attending meetings from Nordic Infucare Ab, has a patent concerning a novel method of minimal non-invasive diagnosis of Parkinson’s disease and is an expert for the Finnish patient injury board. Juho Joutsa, Kari Lindholm, Tero Vahlberg, Tommi Noponen, Toni Ihalainen, Tanja Nojonen, Reeta Levo and Filip Scheperjans report no conflicts of interest.
: The study was accepted by the local ethics committee (Ethics Committee, Hospital District of Southwest Finland) and was conducted according to the 1964 Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.